Efficacy of JAK inhibitors in Ulcerative Colitis.

Abstract

Janus kinase [JAK] inhibitors are a completely novel therapy for the treatment of patients with immune-mediated inflammatory disorders. The oral formulation of tofacitinib has recently been approved for the treatment of moderate-to-severe ulcerative colitis. In the placebo-controlled OCTAVE programme, tofacitinib proved to be efficacious for both inducing and maintaining clinical remission, and this both in anti-tumour necrosis factor-naïve and exposed patients. Several other anti-JAK inhibitors are currently explored. This review summarises the available efficacy data from all anti-JAK inhibitors in ulcerative colitis.

• Authors: Marc Ferrante, João Sabino
• Journal: Journal of Crohn's & colitis (J Crohns Colitis) Vol. 14 Issue Supplement_2 Pg. S737-S745 (Aug 01 2020) ISSN: 1876-4479 [Electronic] England
• PMID: 31879750 (Publication Type: Journal Article, Review)
• Copyright: © European Crohn’s and Colitis Organisation (ECCO) 2019.

Chemical References

• Heterocyclic Compounds, 3-Ring
• Janus Kinase Inhibitors
• Piperidines
• Pyrimidines
• Niacinamide
• upadacitinib
• tofacitinib
• peficitinib
• Adamantane

Topics

• Adamantane (analogs & derivatives, therapeutic use)
• Colitis, Ulcerative (drug therapy)
• Heterocyclic Compounds, 3-Ring (therapeutic use)
• Humans
• Janus Kinase Inhibitors (therapeutic use)
• Niacinamide (analogs & derivatives, therapeutic use)
• Piperidines (therapeutic use)
• Pyrimidines (therapeutic use)
• Treatment Outcome